下肢外周动脉疾病患者低密度脂蛋白胆固醇与高甘油三酯血症管理更新:法国血管医学学会与法国血管及腔内血管外科学会共识
法国多学会共识更新,针对下肢外周动脉疾病(LEAD)患者低密度脂蛋白胆固醇(LDLc)和高甘油三酯血症的管理。由12名血管医生和外科医生组成指导委员会定义问题,46名专家(82%)参与德尔菲投票,4项建议在第一轮后达成共识(超过80%的同意或不同意)。
要点
- LEAD患者经最大耐受剂量他汀±依折麦布治疗后LDLc≥0.70 g/L,推荐加用PCSK9抑制剂。
- LEAD患者经他汀治疗且甘油三酯≥150 mg/dL且≤500 mg/dL,建议加用二十碳五烯酸乙酯。
- 加用二十碳五烯酸乙酯前,建议筛查可能提示心房颤动的症状。
核心结论
- 该更新有助于临床医生改善LEAD患者的管理。
研究设计与样本
- 法国多学会共识,由法国血管医学学会与法国血管及腔内血管外科学会提出,指导委员会由12名血管医生和外科医生组成,定义LDLc和高甘油三酯血症管理的问题。
- 56名专家受邀,46名(82%)接受参与,通过德尔菲程序投票,第一轮后4项建议达成共识(超过80%的同意或不同意)。
主要发现
- 第一轮德尔菲程序后,4项建议均达成共识。
- 建议1:LEAD患者经最大耐受剂量他汀±依折麦布治疗且LDLc≥0.70 g/L,推荐加用PCSK9抑制剂。
- 建议2:LEAD患者经他汀治疗且甘油三酯≥150 mg/dL且≤500 mg/dL,建议加用二十碳五烯酸乙酯。
- 建议3:在加用二十碳五烯酸乙酯前,建议筛查可能提示心房颤动的症状。
- 建议4:使用二十碳五烯酸乙酯且出现心房颤动症状者,推荐进行心电图检查。
关键数值与推荐
- 推荐:LEAD患者经最大耐受剂量他汀±依折麦布治疗且LDLc≥0.70 g/L,加用PCSK9抑制剂。
- 建议(弱推荐):LEAD患者经他汀治疗且甘油三酯≥150 mg/dL且≤500 mg/dL,加用二十碳五烯酸乙酯。
- 建议(弱推荐):加用二十碳五烯酸乙酯前,筛查可能提示心房颤动的症状。
- 推荐:使用二十碳五烯酸乙酯且出现心房颤动症状者,进行心电图检查。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A French intersociety consensus on behalf the Société Française de Médecine Vasculaire and the Société de Chirurgie Vasculaire et Endovasculaire was proposed in 2021 for the management of patients with lower extremity peripheral artery disease (LEAD). Recent studies have been published and an update of this consensus about the management of low-density lipoprotein cholesterol (LDLc) and hypertriglyceridemia was required. METHODS: A steering committee of 12 vascular physicians and surgeons defined questions of interest about LDLc and hypertriglyceridemia management. A French expert panel voted the proposals. Consensus was considered to have been achieved if more than 80% of the responses corresponded to either "Agreement" or "Disagreement". RESULTS: Among the 56 experts who were asked to participate, 46 (82%) accepted. After the first round of the Delphi procedure, the 4 proposals reached consensus. The following suggestions and recommendations were approved: 1. For LEAD patients treated by the highest tolerated statin dose ± ezetimibe and who have an LDLc ≥0.70 g/L, we recommend adding a proprotein convertase subtilisin/kexin type 9 inhibitor. 2. For LEAD patients treated by statin and who have elevated triglyceride level between ≥150 mg/dL and ≤500 mg/dL, we suggest adding Icosapent Ethyl. 3. Before adding Icosapent Ethyl in LEAD patients treated with statin, we suggest looking for symptoms that may suggest atrial fibrillation. 4. For LEAD patients treated by Icosapent Ethyl and who have symptoms that suggest atrial fibrillation, we recommend performing an electrocardiogram. CONCLUSIONS: This update will help clinicians to improve LEAD patient management.
引用
- Mahé G, Boge G, Bura-Rivière A, et al. Update About the Management of Low-Density Lipoprotein Cholesterol and Hypertriglyceridemia in Lower Extremity Peripheral Artery Disease Patients: Consensus of the French Society of Vascular Medicine and the French Society for Vascular and Endovascular Surgery. Ann Vasc Surg. 2023. PMID: 37806655. doi:10.1016/j.avsg.2023.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。